Polypeptide Ligand Modulating GAG Binding Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for controlling interactions between glycosaminoglycans (GAGs) and their effector molecules, such as Otx2 or Semaphorin, are inefficient and lack specificity, hindering the modification of critical periods and nervous system plasticity.
Innovation Solution
Development of a polypeptide ligand comprising a specific sequence of amino acids, including glutamic acid, aspartic acid, cysteic acid, and neutral amino acids, which can interact with GAGs to modulate the binding of effector molecules, thereby controlling critical periods and plasticity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current methods are used to control interactions between GAGs and effector molecules, then the process is simple, but the efficiency and specificity are insufficient
Solution Approach 1:
The ligand is designed as a segmented polypeptide structure with repeating units of specific amino acid sequences (e.g., (ECCA)n or (ECAC)n where n=3-6). Each segment contains charged amino acids that interact with GAGs, allowing modular control of binding specificity and affinity while maintaining a relatively simple overall structure
Solution Approach 2:
The invention controls interaction parameters by varying the amino acid sequence composition, charge distribution, and repetition number (n=3-6) of the polypeptide ligand. These parameter changes enable precise modulation of binding affinity and specificity for different GAG types without requiring complex structural modifications
2Adaptability or versatility
If natural GAG interactions are allowed to proceed without intervention, then the system remains simple, but the ability to modify critical periods and plasticity is limited
Solution Approach 1:
The polypeptide ligand acts as an intermediary molecule that competes with effector molecules (such as Otx2 or Semaphorin) for binding to GAGs. By introducing this mediator, the system gains control over critical period timing and nervous system plasticity while maintaining reliable and specific interactions through the ligand's designed amino acid sequence
3Manufacturing precision
If highly specific ligands are designed to interact with GAG-binding sites, then binding control improves, but the manufacturing complexity increases
Solution Approach 1:
The ligand achieves high binding precision through controlled parameter changes in the amino acid sequence, specifically the repetition number (n=3-6) and composition (ECCA or ECAC units). These parameters can be precisely controlled during standard polypeptide synthesis methods, maintaining ease of manufacture while achieving the required binding precision
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ligand effectively interacts with GAG-binding sites on proteins like Otx2, reducing their binding to GAGs, which can reopen critical periods and enhance nervous system plasticity, offering potential therapeutic benefits for neurological disorders.
Implementation Method 1
These negatively charged groups are believed to figure prominently in the biological properties attributed to glycosaminoglycans... X comprises an amino acid selected from the group consisting of glutamic acid and aspartic acid
Data Source
Figure 1a~2c
Figure 3a~3e
Figure 4a~4c
AI summary
The invention relates to new compounds that mimic Glycosaminoglycans and are able to control interaction between Glycosaminoglycans with their effector molecules. The compounds of the invention are peptides and are able to prevent or reduce the binding of at least one effector molecule with at least one glycosaminoglycan. The compounds according to the invention can be used as drug, in particular for the stimulation of the neurogenesis and more generally to treat nervous system related pathologies.